Advertisement

Cancer and Metastasis Reviews

, Volume 31, Supplement 1, pp 29–32 | Cite as

The role of pharmacogenomics in metastatic renal cell carcinoma

  • Daniel Castellano
  • Juan Antonio Virizuela
  • Josefina Cruz
  • Juan Manuel Sepulveda
  • Maribel Sáenz
  • Luís Paz-AresEmail author
Article

Abstract

Pharmacogenomics is the study of how variation in the genetic background affects an individual’s response to a specific drug and/or its metabolism. Using knowledge about the genes which produce the enzymes that metabolize a specific drug, a physician may decide to raise or lower the dose, or even change to a different drug. Targeted therapy with tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors has led to a substantial improvement in the standard of care for patients with advanced or metastatic renal cell carcinoma (RCC). Although few studies have identified biomarkers that predict the response of targeted drugs in the treatment of metastatic RCC, some associations have been found. Several studies have identified genetic polymorphisms with implications in the pharmacokinetics and/or pharmacodynamics of TKIs and mTOR inhibitors and which are associated with a prolonged progression-free survival and/or overall survival in patients with metastatic RCC. Among the genes of interest, we should consider IL8, FGFR2, VEGFA, FLT4, and NR1I2. In this review, we discuss single nucleotide polymorphisms (SNPs) associated with outcome and toxicity following targeted therapies and provide recommendations for future trials to facilitate the use of SNPs in personalized therapy for this disease.

Keywords

Single nucleotide polymorphisms Pharmacokinetic Pharmacodynamic Biomarkers 

Notes

Acknowledgments

The authors acknowledge the support of Novartis Oncology Spain, which has facilitated the necessary meetings to evaluate and discuss all the data presented in this review, and Dr. Fernando Sánchez-Barbero from HealthCo SL (Madrid, Spain) for assistance in the preparation of this manuscript.

Conflict of interest

The authors declare that they do not have any conflict of interest that may inappropriately influence this work.

References

  1. 1.
    Ingelman-Sundberg, M. (2001). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine, 250, 186–200.PubMedCrossRefGoogle Scholar
  2. 2.
    Evans, W. E., & Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9–39.PubMedCrossRefGoogle Scholar
  3. 3.
    US Food and Drug Administration. (2012). Table of pharmacogenomic biomarkers in drug labels. US Food and Drug Administration. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed 19 June 2012Google Scholar
  4. 4.
    Brookes, A. J. (1999). The essence of SNPs. Gene, 234, 177–186.PubMedCrossRefGoogle Scholar
  5. 5.
    Belle, D. J., & Singh, H. (2008). Genetic factors in drug metabolism. American Family Physician, 77, 1553–1560.PubMedGoogle Scholar
  6. 6.
    Giacomini, K. M., Brett, C. M., Altman, R. B., et al. (2007). The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics, 81, 328–345.PubMedCrossRefGoogle Scholar
  7. 7.
    van Erp, N. P., Eechoute, K., van der Veldt, A. A., et al. (2009). Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. Journal of Clinical Oncology, 27, 4406–4412.PubMedCrossRefGoogle Scholar
  8. 8.
    Shukla, S., Robey, R. W., Bates, S. E., et al. (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 37, 359–365.PubMedCrossRefGoogle Scholar
  9. 9.
    Xu, C. F., Reck, B. H., Goodman, V. L., et al. (2011). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of Hepatology, 54, 1237–1243.PubMedCrossRefGoogle Scholar
  10. 10.
    Tran, H. T., Liu, Y., Lin, Y., et al. (2010). Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. Journal of Clinical Oncology, 28(15s (Abstr 4522)).Google Scholar
  11. 11.
    Staehler, M., Rohrmann, K., Haseke, N., et al. (2005). Targeted agents for the treatment of advanced renal cell carcinoma. Current Drug Targets, 6, 835–846.PubMedCrossRefGoogle Scholar
  12. 12.
    Vogelzang, N. J. (2006). Treatment options in metastatic renal carcinoma: an embarrassment of riches. Journal of Clinical Oncology, 24, 1–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Vaziri, S. A., Kim, J., Ganapathi, M. K., et al. (2010). Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Current Oncology Reports, 12, 102–108.PubMedCrossRefGoogle Scholar
  14. 14.
    Ball, H. A., Xu, C. & Sternberg, C. N. et al. (2010) Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma. In: ASCO Meeting Abstracts 28, p. 4520.Google Scholar
  15. 15.
    Xu, C., Ball, H. A., Bing, N., et al. (2011). Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma. ASCO Meeting Abstracts, 29, 303.Google Scholar
  16. 16.
    Garcia-Donas, J., Esteban, E., Leandro-Garcia, L. J., et al. (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology, 12, 1143–1150.PubMedCrossRefGoogle Scholar
  17. 17.
    van der Veldt, A. A., Eechoute, K., Gelderblom, H., et al. (2011). Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clinical Cancer Research, 17, 620–629.PubMedCrossRefGoogle Scholar
  18. 18.
    Swanton, C., Larkin, J. M., Gerlinger, M., et al. (2010). Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2, 53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Daniel Castellano
    • 1
  • Juan Antonio Virizuela
    • 2
  • Josefina Cruz
    • 3
  • Juan Manuel Sepulveda
    • 1
  • Maribel Sáenz
    • 4
  • Luís Paz-Ares
    • 5
    Email author
  1. 1.Hospital Universitario 12 de OctubreMadridSpain
  2. 2.Hospital Universitario Virgen de la MacarenaSevillaSpain
  3. 3.Hospital Nuestra Señora de la CandelariaSanta Cruz de TenerifeSpain
  4. 4.Hospital Universitario Virgen de la VictoriaMálagaSpain
  5. 5.Instituto de Biomedicina de SevillaHospital Universitario Virgen del RocíoSevillaSpain

Personalised recommendations